Particularly, a specific inhibitor of TAOK3, SBI‐581, is identified, which can synergize with cisplatin and subsequently enhance the effectiveness of chemotherapy in ESCC. This evidence concerns the gene TAOK3 and esophageal squamous cell carcinoma.